Liquidity (Details Narrative) - USD ($) |
1 Months Ended | |||||
|---|---|---|---|---|---|---|
Jan. 30, 2019 |
Jan. 03, 2019 |
Apr. 30, 2019 |
Jun. 30, 2019 |
May 31, 2019 |
Dec. 31, 2018 |
|
| Accumulated deficit | $ (145,452,396) | $ (121,370,240) | ||||
| Accounts payable | 7,490,561 | 6,345,335 | ||||
| Cash and cash equivalents | 73,154,916 | $ 41,748,468 | ||||
| Cystic Fibrosis Program Related Investment Agreement [Member] | ||||||
| Percentage of payment from the upfront payment received | 10.00% | |||||
| Accounts payable | $ 2,700,000 | |||||
| Cystic Fibrosis Program Related Investment Agreement [Member] | 2018 CFF Award [Member] | ||||||
| Milestone received on achievement on clinical trial | $ 17,500,000 | $ 5,000,000 | ||||
| Maximum amount received as development award as funding | $ 25,000,000 | |||||
| Cystic Fibrosis Program Related Investment Agreement [Member] | Cystic Fibrosis Foundation [Member] | ||||||
| Milestone received on achievement on clinical trial | $ 5,000,000 | |||||
| Kaken Pharmaceutical Co., Ltd. [Member] | ||||||
| Upfront payment received from strategic collaboration | $ 27,000,000 | |||||
| Underwritten Public Offering [Member] | ||||||
| Net proceeds | $ 37,700,000 |
| X | ||||||||||
- Definition Maximum amount received as development award as funding. No definition available.
|
| X | ||||||||||
- Definition Milestone received on achievement on clinical trial. No definition available.
|
| X | ||||||||||
- Definition Percentage of payment from the upfront payment received. No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Cash received from collaborators during the current period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow associated with the amount received from entity's first offering of stock to the public. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|